Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 12/20 | 0.37 |
| ▸ | MMP13 | P45452 | 11/20 | 0.35 |
| ▸ | MMP3 | P08254 | 4/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27615261 | 0.79 | SMN1; SMN2 (0.42) | HSD17B10MMP8 | |
| SCHEMBL4872670 | 0.78 | KDM4E (0.31) | HSD17B10 | |
| SCHEMBL4872665 | 0.78 | — | — | |
| SCHEMBL4874698 | 0.72 | FOLH1 (0.39) | — | |
| SCHEMBL4871262 | 0.69 | MEN1 (0.39) | HSD17B10MMP8 | |
| SCHEMBL4874207 | 0.68 | CYP26B1 (0.44) | — | |
| SCHEMBL3516029 | 0.64 | GRM3 (0.40) | — | |
| SCHEMBL27615259 | 0.64 | SMN1; SMN2 (0.49) | HSD17B10MMP1 | |
| SCHEMBL31516059 | 0.64 | HSD17B10 (0.53) | HSD17B10MMP1MMP13MMP3MMP2 | |
| SCHEMBL4872675 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | HSD17B10 1740/4885MMP1 4142/4885MMP13 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.